Elranatamab in Refractory Multiple Myeloma with Prior BCMA Therapies
Evaluating the safety and efficacy of elranatamab
Dr. Ajay Nooka presents the efficacy and safety analysis of a drug called elranatamab in patients with refractory multiple myeloma who had prior exposure to BCMA-directed therapies. Elranatamab is a humanized bispecific antibody that targets both BCMA-expressing myeloma cells and silica-expressing T cells.
The pooled analysis included data from the ongoing phase 2 MAGNITUDE-3 study and evaluated the monotherapy of elranatamab in BCM-naive patients with relapsed/refractory myeloma. The analysis included a total of 87 patients, of which 59 received a prior antibody-drug conjugate (ADC) and 36 received a prior CAR-T therapy. The median age of patients in the ADC cohort was younger, and high-risk cytogenetics were observed in 30% of the patients. The median lines of therapy were seven overall. The study showed an overall response rate of 61% and a median duration of response that has not been reached yet. The safety profile of elranatamab was consistent with that of BCM-naive patients.
- Elranatamab is a humanized bispecific antibody used in the treatment of refractory multiple myeloma.
- The pooled analysis included data from the phase 2 MAGNITUDE-3 study.
- The study evaluated the efficacy and safety of elranatamab monotherapy in BCM-naive patients with relapsed/refractory myeloma.
- The analysis included a total of 87 patients, with 59 patients receiving a prior ADC and 36 patients receiving a prior CAR-T therapy.
- The median age of patients in the ADC cohort was younger, and high-risk cytogenetics were observed in 30% of the patients.
- The median lines of therapy were seven overall.
- The overall response rate was 61%, and the median duration of response has not been reached yet.
- The safety profile of elranatamab was consistent with that of BCM-naive patients.
Authors:
Ajay K. Nooka, Alexander M. Lesokhin, Mohamad Mohty, Ruben Niesvizky, Christopher Maisel, Bertrand Arnulf, Sarah Marie Larson, Asya Varshavsky Yanovsky, Xavier P Leleu, Lionel Karlin, David H. Vesole, Nizar J. Bahlis, Carlos Fernández de Larrea, Noopur S. Raje, Eric Leip, Umberto Conte, Mohamed Elmeliegy, Andrea Viqueira, Salomon Manier
Doctor Bio:
Ajay Kumar Nooka, MD, MPH, FACP, is an Associate Professor and serves as director of the Myeloma Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also serves as medical director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute of Emory University. An Emory Healthcare network physician since 2011, Dr. Nooka is a board-certified hematologist specializing in the treatment of patients with multiple myeloma.
